BridgeBio Pharma Inc (BBIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at BridgeBio Pharma Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 80.10 $ — 78% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 86.3% passed
- More than 10% revenue growth is expected for the coming year 65.3% passed
- Share count grows by less than 3% a year 10.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 37.2% failed
- Gross margin at 40% or higher and without meaningful erosion 94.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 414 m failed
- Return on capital at 15% or higher, or up versus two years ago -87.8% failed
- Insiders hold at least 10% or are net buyers 3.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 31.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 19
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.14 | -2.58 – -1.50 | 961 | 43.4% | 8 |
| 12/31/2027 | 0.57 | -1.30 – 2.19 | 1,609 | 126.6% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.63 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.40 | – | 6 | 237.10 | -4,506.10 | -195 | -199 |
| 2025: Q1 | -0.88 | – | 117 | -44.80 | -143.50 | -199 | -201 |
| 2025: Q2 | -0.95 | – | 111 | 4,999.90 | -164.50 | -81 | -86 |
| 2025: Q3 | -0.96 | – | 121 | 4,318.00 | -151.40 | -110 | -110 |
| 2025: Q4 | -1.00 | – | 154 | 2,521.20 | -127.90 | -56 | -61 |
| 2026: Q1 | -0.84 | – | 195 | 66.80 | -84.30 | -197 | -197 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -44 | -31 | -0.33 | -40 | -58 | 98 |
| 2018 | 0 | -184 | -131 | -1.42 | -137 | -164 | 465 |
| 2019 | 41 | -266 | -260 | -2.48 | -254 | 408 | 632 |
| 2020 | 8 | -474 | -449 | -3.80 | -400 | 58 | 704 |
| 2021 | 70 | -577 | -563 | -3.90 | -498 | -870 | 1,013 |
| 2022 | 78 | -512 | -481 | -3.26 | -419 | -1,255 | 623 |
| 2023 | 9 | -607 | -643 | -3.95 | -528 | -1,354 | 546 |
| 2024 | 222 | -593 | -536 | -2.88 | -521 | -1,468 | 919 |
| 2025 | 502 | -569 | -729 | -3.70 | -446 | -2,077 | 936 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
BridgeBio Pharma, Inc. ist ein biopharmazeutisches Unternehmen, das Medikamente für Patienten mit genetischen Erkrankungen entdeckt, entwickelt und liefert.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 834 |
| Headquarters | Palo Alto, CA |
| Address | 3160 Porter Drive, 94304 Palo Alto, United States |
| Phone | 650 391 9740 |
| Website | bridgebio.com |
| IPO Date | 27. Jun 2019 |
| ISIN | US10806X1028 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Neil Kumar Ph.D. | Co-Founder, CEO & Director | 1979 |
| Thomas Trimarchi Ph.D. | CFO & President | 1985 |
| Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Lead Director | 1948 |
| Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director | 1950 |
| Maricel M. Apuli | Chief Accounting Officer | 1977 |
| Uma Sinha Ph.D. | Chief Scientific Officer | 1958 |
| Richard H. Scheller Ph.D. | Chairman of Research & Development | 1953 |
| Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology | 1967 |
| Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy | 1972 |
| Matthew Outten CPC, MBA | Chief Commercial Officer | 1974 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 9. Jul 2026 | Ellis Andrea | Director | Sell | 17,167 | 84.00 | 1,442,028 |
| 9. Jul 2026 | Ellis Andrea | Director | Other | 17,167 | 16.75 | 287,547 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Sell | 112,422 | 90.00 | 10,117,980 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Sell | 36,167 | 84.00 | 3,038,028 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 17,167 | 16.75 | 287,547 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 112,422 | 29.00 | 3,260,238 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 19,000 | 8.45 | 160,550 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.